Resources by service
Development of a Novel Blinding Methodology for a Market Leading Dry-Powder Inhaler (DPI)
A mid-sized pharmaceutical company was planning to enter a phase III trial with a promising new treatment for asthma and COPD. To eliminate bias, the client’s clinical team had designed a double-blind clinical trial. While manufacturing active and placebo forms of their own product was possible, developing a method to blind their product against the visually different active comparator was more of a challenge. The company approached Almac to help solve this problem. Almac had never handled this product before, and within a limited time frame we had to develop and validate a cost effective, reliable and reproducible blinding method capable of handling the volumes required to support the client’s planned clinical trial demand.
Innovation is one of Almac’s core values. Almac’s unique inhaler blinding services provide a perfect illustration of this. While Almac has already developed and validated clinical blinding techniques for most leading inhalers, continued launches of new inhalers mean we consistently face new challenges in this specialised area of clinical trial supplies.
Click here to discover more about Almac Clinical Services
*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to [email protected]. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list.
